Table 2.
Pharmacological Activities of bioactive compounds (main peaks selected) present in TSLME
| Peak | Compound Name | Retention Time (Min) | Area (%) | Pharmacological Activities (Reference) |
|---|---|---|---|---|
| 1 | Cyclopentadiene, 1,2,3,4,5-pentamethyl- | 6.107 | 0.21 | NAR |
| 2 | Decane | 7.641 | 0.54 | AM [33] |
| 3 | Vanillin | 8.639 | 0.34 | AO, AIF, NRP, AC [34–36] |
| 4 | Phenethylamine, 3,4,5-trimethoxy- α-methyl- | 9.012 | 0.17 | NAR |
| 5 | Cyclopentasiloxane, decamethyl | 10.241 | 0.20 | AM [37] |
| 6 | 3,4-Dihydroxyphenol ethanol ( 3-hydroxytyrosol) | 11.683 | 0.18 | AO, NRP [38, 39]; AT, AP [40–42]; AM [43] |
| 7 | Cyclohexasiloxane, dodecamethyl | 12.897 | 0.24 | AM [44]; AFG [45]; AB, AFL, IMD and AT [46] |
| 8 | Mandelic acid, 3,4-dihydroxy, (4TMS) | 14.031 | 0.42 | AM,AO [47, 48] |
| 9 | Cholan-12-one, 3-(acetyloxy)-, (3α. 5β.)- | 14.958 | 0.30 | NAR |
| 10 | Cycloheptasiloxane, tetradecamethyl | 15.301 | 0.59 | AM [44]; AFG [45]; AB, AFL, IMD and AT [46] |
| 11 | 1-Bromotetradecane ( Myristyl bromide) | 15.561 | 0.44 | NAR |
| 12 | Cyclododecasiloxane, tetracosamethyl | 16.276 | 6.27 | AFG [45];HP, ASP, ARH [49] |
| 13 | 1,2-Benzenedicarboxylic acid, diethyl ester | 17.256 | 6.85 | AM, AFG, AMR [50]; AC, CT [51] |
| 14 | 2-Cyclohepten-1-one ( Tropilene) | 17.832 | 1.39 | NAR |
| 15 | 1,1,3,3,5,5,7,7,9,9,11,11Dodecamethylhexasiloxane | 18.279 | 2.22 | AM, AST [53] |
| 16 | Cyclooctasiloxane, hexadecamethyl | 18.646 | 0.75 | AM [44] |
| 17 | D-Xylitol | 18.850 | 1.06 | NAR |
| 18 | 9-Octadecenoic acid, 2-[(trimethylsilyl)oxy]−1-[[(trimethylsilyl)oxy]methyl]ethyl ester | 19.189 | 0.83 | AC, HP [54] |
| 19 | 1,1,3,3,5,5,7,7,9,9,11,11,13,13,15,15-Hexadecamethyl-Octasiloxane | 20.258 | 1.92 | AM [55] |
| 20 | Cyclodecasiloxane, eicosamethyl- | 20.845 | 3.30 | AM, AHT, AO [55] |
| 21 | Iron, monocarbonyl-(1,3-butadiene-1,4-dicarbonic acid, diethyl ester), a, a’-dipyridyl | 21.244 | 1.01 | NAR |
| 22 | 6,10-Dodecadien-3-ol, 3,7,11-trimethyl- ( 2,3-Dihydrofarnesol) | 21.576 | 3.34 | NAR |
| 23 | 2,6,10,14,18,22-Tetracosahexaene, 2,6,10,15,19,23-hexamethyl- ( Squalene) | 21.969 | 1.33 | AB, AO, AC, CP [56–59] |
| 24 | 1H-Purin-6-amine, [(2-fluorophenyl)methyl]- | 22.381 | 4.77 | AO [60] |
| 25 | 5-Pregnene-3β,20β,21-triol TMS | 22.815 | 1.01 | NAR |
| 26 | Imidazo[4,5,1-jk][1, 4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]−5,6-dihydro- | 23.575 | 1.15 | NAR |
| 27 | Ethyl 1-hexyl-4-hydroxy-2(1H)-oxo-3 quinolinecarboxylate | 23.927 | 0.62 | NAR |
| 28 | 3-Chlorodecanoic acid, chloromethyl ester | 24.207 | 0.33 | NAR |
| 29 | Purine, 6-(3-methyl-2-butenyl)amino, TMS | 24.920 | 0.32 | AP [61] |
| 30 | Cyclononasiloxane, octadecamethyl | 25.843 | 4.38 | AFG [62]; AO [63, 64] |
AM Antimicrobial, AB Antibacterial, AT Antitumor, HP Hepatoprotective, AO Antioxidant, AC Anticancer, NAR No Activity Reported, CP Chemopreventive, AP Antiproliferative, AFG Antifungal, AFL Antifouling, AIF Anti-inflammatory, IM )Immunomodulatory, ASP Antispasmodic, ART Antirheumatic, AMR Antimalarial, CT Cytotoxicity, AHT Anthelmintic, NRP Neuroprotective, AST Antiseptic